Hospital Universitario Severo Ochoa

Leganes 25 trials 10 recruiting

25 Registered trials

10 Currently recruiting

Organisation

Hospital Universitario Severo Ochoa

Location

Leganes, Spain

Identifier

ORG-100032738

Address

Avenida Orellana S/n, 28911, Spain

Departments

-
Cardiología
Cardiology
ES001:Pediatría
Internal Medicine
Medical oncology
Nefrology
Nephrology
Obstetrician and Gynecologist
Oncolgy
Oncology
Oncology Service
Pediatría
Pediatric
Urgencias

Clinical trials at this site (25)

Search interface

A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending

2024-514248-95-00 Uncontrolled Asthma 5
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and … Pending

2025-521989-95-00 Advanced/Metastatic Non-squamous Non-Small Cell Lung Ca 9
Optimizing Aspirin Use for Preeclampsia Prevention Pending

2025-524646-94-00 Obstetrics – Preeclampsia 11
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
A Study of YL201 in Patients With Advanced Solid Tumors Recruiting

2024-517589-41-00 Advanced solid tumors 1 2025-08-04
Study of the treatment of patients with non-small cell lung cancer with metastasis with Cemiplimab and subsequent treatment with Cemiplimab … Recruiting

2024-518812-38-00 Non-small cell lung cancer (NSCLC) 4 2025-07-02
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) versus Conventional Treatment in Acute Myocarditis: INFLAMA study Recruiting

2024-513803-15-00 Acute myocarditis 6 2025-01-30
COLCHICINE IN SECONDARY PREVENTION OF VASCULAR EVENTS AND RENAL PROGRESSION IN PATIENTS WITH MODERATE CHRONIC RENAL DISEASE Recruiting

2023-505868-11-00 CHRONIC RENAL DISEASE 5 2025-01-17
An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients Recruiting

2024-512161-14-00 Breast Cancer 3 2025-01-14
A Randomized Clinical Trial, Multicentre, Open-label, Parallel-group, to define the best Strategy for the management of hEart failure aNd ch… Recruiting

2024-513971-42-00 Chronic heart failure (NYHA I-III) and non-dialysis CKD 5 2024-10-01
VACCINE EFFECTIVENESS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AGAINST VACCINE-TYPE CAP USING A TEST-NEGATIVE DESIGN Recruiting

2023-507293-40-00 VACCINE-TYPE RADIOLOGICALLY-CONFIRMED COMMUNITY-ACQUIRE 6 2024-04-11
A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR) Recruiting

2024-513562-19-00 End-Stage Kidney Disease 5 2023-08-30
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer p… Ended

2023-507438-25-00 Non-small cell lung cancer 2 2024-02-28
Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squam… Ended

2023-507448-36-00 Non-small Cell Lung Cancer 5 2024-02-16
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea… Ended

2024-514630-21-00 HER2 positive (HER2+), Hormone Receptor positive (HR+) 4 2022-08-11
A research study to evaluate the activity of Sotorasib for the treatment of patients with non-operable non-small cell lung cancer with a KRA… Ended

2024-511268-10-00 Unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12 4 2022-05-25
Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: (REMOVE) Ended

2023-504946-70-00 Heart Failure 6 2021-12-01
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended

2023-505223-31-00 Localized ER+ breast cancer 4 2019-06-14
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months Ended

2022-502022-41-00 Acute lower respiratory infection 3 2024-05-28
Safety and Immunogenicity of V116 in Children and Adolescents With Increased Risk for Pneumococcal Disease Ended

2023-506236-32-00 Pneumococcal disease 5 2024-03-25
Study of Atezolizumab plus chemotherapy plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable non-small cell lung c… Ended

2024-514803-33-00 Non-small cell lung cancer (NSCLC) 4 2021-06-16